The role of platelet activation in tumor metastasis

References

• Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb. Res.102, V215–V224 (2001).
   PubMed Web of Science ®Google Scholar
• Varki A. Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood110, 1723–1729 (2007).
   PubMed Web of Science ®Google Scholar
• Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol.3, 425–430 (2002).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN. Thrombosis and cancer: implications beyond Trousseau. J. Thromb. Haemost.2, 1261–1262 (2004).
   Google Scholar
• Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interactionin vitro and metastasis formation in vivo.J. Clin. Invest.81, 1012–1019 (1988).
   PubMed Web of Science ®Google Scholar
• Boccaccio C, Sabatino G, Medico E et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature434, 396–400 (2005).
   PubMed Web of Science ®Google Scholar
• Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann. Intern. Med.95, 636–641 (1981).
   PubMed Web of Science ®Google Scholar
• Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev.3, 99–114 (1984).
   PubMed Web of Science ®Google Scholar
• Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin. Thromb. Hemost.18, 392–415 (1992).
   PubMed Web of Science ®Google Scholar
• Jurasz P, Alonso-Escolano D, Radomski MW. Platelet – cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol.143, 819–826 (2004).
   PubMed Web of Science ®Google Scholar
• Burdick MM, Konstantopoulos K. Platelet-induced enhancement of LS174T colon carcinoma and THP-1 monocytoid cell adhesion to vascular endothelium under flow. Am. J. Physiol. Cell Physiol.287, C539–C547 (2004).
   PubMed Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin. Thromb. Hemost.33, 712–721 (2007).
   Google Scholar
• Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation112, 2725–2734 (2005).
   PubMed Web of Science ®Google Scholar
• Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev.21, 99–111 (2007).
   PubMed Web of Science ®Google Scholar
• Brass LF. Thrombin and platelet activation. Chest124, 18S–111 (2003).
   Web of Science ®Google Scholar
• Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets12, 261–273 (2001).
   PubMed Web of Science ®Google Scholar
• Smith WL. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol.263, F181–F191 (1992).
   PubMed Web of Science ®Google Scholar
• Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J. Thromb. Haemost.1, 1897–1905 (2003).
   PubMed Web of Science ®Google Scholar
• Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb. Res.121, 535–542 (2008).
   PubMed Web of Science ®Google Scholar
• Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler. Thromb. Vasc. Biol.25, 1512–1518 (2005).
   PubMed Web of Science ®Google Scholar
• Von Hundelshausen P, Weber KS, Huo Y et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation103, 1772–1777 (2001).
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature391, 591–594 (1998).
   PubMed Web of Science ®Google Scholar
• Danese S, de La Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J. Immunol.172, 2011–2015 (2004).
   PubMed Web of Science ®Google Scholar
• Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler. Thromb. Vasc. Biol.28, S17–S24 (2008).
   PubMed Web of Science ®Google Scholar
• Bugert P, Dugrillon A, Gunaydin A, Eichler H, Kluter H. Messenger RNA profiling of human platelets by microarray hybridization. Thromb. Haemost.90, 738–748 (2003).
   PubMed Web of Science ®Google Scholar
• Denis MM, Tolley ND, Bunting M et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell122, 379–391 (2005).
   PubMed Web of Science ®Google Scholar
• Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev.11, 237–248 (1992).
   PubMed Web of Science ®Google Scholar
• Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N. Engl. J. Med.287, 999–1005 (1972).
   PubMed Web of Science ®Google Scholar
• Costantini V, Zacharski LR, Moritz TE, Edwards RL. The platelet count in carcinoma of the lung and colon. Thromb. Haemost.64, 501–505 (1990).
   Google Scholar
• Boneu B, Bugat R, Boneu A, Eche N, Sie P, Combes PF. Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathy. Eur. J. Cancer Clin. Oncol.20, 899–903 (1984).
   Google Scholar
• Pinedo HM, Verheul HM, D’amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet352, 1775–1777 (1998).
   PubMed Web of Science ®Google Scholar
• Zacharski LR. Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett.186, 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis14, 109–122 (1994).
   PubMedGoogle Scholar
• Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol.2, 608–613 (2001).
   PubMed Web of Science ®Google Scholar
• Borsig L, Stevenson JL, Varki A. Heparin in cancer: role of selectin interactions. In: Cancer-Associated Thrombosis. Khorana AA, Francis CW (Eds). Informa Healthcare, NY, USA 97–113 (2007).
   Google Scholar
• Shivdasani RA, Rosenblatt MF, Zucker-Franklin D et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell81, 695–704 (1995).
   PubMed Web of Science ®Google Scholar
• Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood104, 397–401 (2004).
   PubMed Web of Science ®Google Scholar
• Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell10, 355–362 (2006).
   PubMed Web of Science ®Google Scholar
• Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA98, 3352–3357 (2001).
   PubMed Web of Science ®Google Scholar
• Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc. Natl Acad. Sci. USA89, 11832–11836 (1992).
   PubMed Web of Science ®Google Scholar
• Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res.66, 10643–10646 (2006).
   PubMed Web of Science ®Google Scholar
• Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin. Thromb. Hemost.32(Suppl. 1), 61–68 (2006).
   PubMedGoogle Scholar
• Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol. Haemost. Thromb.35, 103–110 (2006).
   PubMed Web of Science ®Google Scholar
• Giesen PL, Rauch U, Bohrmann B et al. Blood-borne tissue factor: another view of thrombosis. Proc. Natl Acad. Sci. USA96, 2311–2315 (1999).
   PubMed Web of Science ®Google Scholar
• Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin. Thromb. Hemost.32, 54–70 (2006).
   PubMed Web of Science ®Google Scholar
• Wang X, Wang M, Amarzguioui M, Liu F, Fodstad O, Prydz H. Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int. J. Cancer112, 994–1002 (2004).
   Google Scholar
• Nierodzik ML, Chen K, Takeshita K et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood92, 3694–3700 (1998).
   PubMed Web of Science ®Google Scholar
• Costantini V, Zacharski LR. Fibrin and cancer. Thromb. Haemost.69, 406–414 (1993).
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Kombrinck KW, Drew AF et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood96, 3302–3309 (2000).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl Acad. Sci. USA95, 9325–9330 (1998).
   PubMed Web of Science ®Google Scholar
• Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E. Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb. Res.79, 261–274 (1995).
   Google Scholar
• Clezardin P, Drouin J, Morel-Kopp MC et al. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells. Cancer Res.53, 4695–4700 (1993).
   Google Scholar
• Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesionin vitro and metastasis in vivo.Thromb. Haemost.74, 282–290 (1995).
   Google Scholar
• Trikha M, Zhou Z, Timar J et al. Multiple roles for platelet GPIIb/IIIa and avb3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res.62, 2824–2833 (2002).
   PubMed Web of Science ®Google Scholar
• Jain S, Zuka M, Liu J et al. Platelet glycoprotein Iba supports experimental lung metastasis. Proc. Natl Acad. Sci. USA104, 9024–9028 (2007).
   PubMedGoogle Scholar
• Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl Acad. Sci. USA99, 2193–2198 (2002).
   PubMed Web of Science ®Google Scholar
• Mcever RP. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj. J.14, 585–591 (1997).
   PubMedGoogle Scholar
• Kansas GS. Selectins and their ligands: current concepts and controversies. Blood88, 3259–3287 (1996).
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Boehme B, Podda M et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res.64, 2743–2750 (2004).
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res.59, 1295–1300 (1999).
   PubMed Web of Science ®Google Scholar
• Fuster MM, Brown JR, Wang L, Esko JD. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res.63, 2775–2781 (2003).
   PubMed Web of Science ®Google Scholar
• Palumbo JS, Talmage KE, Massari JV et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood110, 133–141 (2007).
   PubMed Web of Science ®Google Scholar
• Floyd CM, Irani K, Kind PD, Kessler CM. von Willebrand factor interacts with malignant hematopoietic cell lines: evidence for the presence of specific binding sites and modification of von Willebrand factor structure and function. J. Lab. Clin. Med.119, 467–476 (1992).
   Google Scholar
• Terraube V, Pendu R, Baruch D et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J. Thromb. Haemost.4, 519–526 (2006).
   Google Scholar
• Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry24, 5558–5567 (1985).
   PubMed Web of Science ®Google Scholar
• Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseau’s syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res.61, 795–798 (2001).
   PubMed Web of Science ®Google Scholar
• Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J. Thromb. Haemost.3, 1590–1596 (2005).
   PubMed Web of Science ®Google Scholar
• Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J. Clin. Invest.112, 853–862 (2003).
   PubMed Web of Science ®Google Scholar
• Salgado R, Vermeulen PB, Benoy I et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br. J. Cancer80, 892–897 (1999).
   PubMed Web of Science ®Google Scholar
• Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin. Breast Cancer2, 311–315 (2002).
   PubMed Web of Science ®Google Scholar
• Kim HK, Song KS, Park YS et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur. J. Cancer39, 184–191 (2003).
   PubMed Web of Science ®Google Scholar
• Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood96, 4216–4221 (2000).
   PubMed Web of Science ®Google Scholar
• Mcdowell G, Temple I, Li C et al. Alteration in platelet function in patients with early breast cancer. Anticancer Res.25, 3963–3966 (2005).
   Google Scholar
• Verheul HM, Hoekman K, Lupu F et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin. Cancer Res.6, 166–171 (2000).
   PubMed Web of Science ®Google Scholar
• Trikha M, Nakada MT. Platelets and cancer: implications for antiangiogenic therapy. Semin. Thromb. Hemost.28, 39–44 (2002).
   PubMed Web of Science ®Google Scholar
• Boucharaba A, Serre CM, Gres S et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest.114, 1714–1725 (2004).
   PubMed Web of Science ®Google Scholar
• Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer3, 582–591 (2003).
   PubMed Web of Science ®Google Scholar
• Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem.73, 321–354 (2004).
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia3, 371–384 (2001).
   PubMed Web of Science ®Google Scholar
• Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature386, 616–619 (1997).
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Eldor A, Haimovitz-Friedman A et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis12, 112–127 (1992).
   PubMedGoogle Scholar
• Belloc C, Lu H, Soria C, Fridman R, Legrand Y, Menashi S. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int. J. Cancer60, 413–417 (1995).
   PubMed Web of Science ®Google Scholar
• Janowska-Wieczorek A, Wysoczynski M, Kijowski J et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer113, 752–760 (2005).
   PubMed Web of Science ®Google Scholar
• Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion46, 1199–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Alonso-Escolano D, Medina C, Cieslik K et al. Protein kinase C d mediates platelet-induced breast cancer cell invasion. J. Pharmacol. Exp. Ther.318, 373–380 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen SA, Trikha M, Mascelli MA. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol. Oncol. Res.6, 163–174 (2000).
   PubMedGoogle Scholar
• Amirkhosravi A, Mousa SA, Amaya M et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb. Haemost.90, 549–554 (2003).
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Schon MP, Boehncke WH. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin. Ther. Targets11, 1103–1117 (2007).
   PubMed Web of Science ®Google Scholar
• Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin. Ther. Targets11, 1473–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Laubli H, Stevenson JL, Varki A, Varki NM, Borsig L. L-selectin facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of tumor cell arrest. Cancer Res.66, 1536–1542 (2006).
   PubMed Web of Science ®Google Scholar
• Hostettler N, Naggi A, Torri G, Casu B, Vlodavsky I, Borsig L. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J.21, 3562–3572 (2007).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol.22, 1944–1948 (2004).
   PubMed Web of Science ®Google Scholar
• Klerk CP, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol.23, 2130–2135 (2005).
   PubMed Web of Science ®Google Scholar
• Lee AY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol.23, 2123–2129 (2005).
   PubMed Web of Science ®Google Scholar
• Altinbas M, Coskun HS, Er O et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost.2, 1266–1271 (2004).
   PubMed Web of Science ®Google Scholar
• Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost.28, 53–66 (2002).
   PubMed Web of Science ®Google Scholar
• Varki A, Varki NM. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz. J. Med. Biol. Res.34, 711–717 (2001).
   PubMedGoogle Scholar
• Borsig L. Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol. Sci.19, 16–21 (2004).
   PubMedGoogle Scholar
• Garcia J, Callewaert N, Borsig L. P-selectin mediates metastatic progression through binding to sulfatides on carcinoma cells. Glycobiology17, 185–196 (2007).
   PubMed Web of Science ®Google Scholar
• Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins – correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res.11, 7003–7011 (2005).
   PubMed Web of Science ®Google Scholar
• Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Invest.101, 877–889 (1998).
   PubMed Web of Science ®Google Scholar